1. bookVolume 29 (2021): Edition 4 (October 2021)
Détails du magazine
License
Format
Magazine
eISSN
2284-5623
Première parution
08 Aug 2013
Périodicité
4 fois par an
Langues
Anglais
access type Accès libre

Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia

Publié en ligne: 22 Oct 2021
Volume & Edition: Volume 29 (2021) - Edition 4 (October 2021)
Pages: 377 - 385
Reçu: 22 Jul 2021
Accepté: 01 Oct 2021
Détails du magazine
License
Format
Magazine
eISSN
2284-5623
Première parution
08 Aug 2013
Périodicité
4 fois par an
Langues
Anglais
Abstract

Introduciton: COVID19 is one of the largest pandemics. Since December 2019 until now the coronavirus has infected over 131 million people. The mortality rate in the general population varies between 1 to 5%, with a potential of over 30% in patients with neoplasms.

Methods: The main objective of the study was to identify some peculiarities of the evolution, complications and treatment of patients with acute leukaemia and COVID-19. The study was retrospective and included 50 patients with acute leukaemia and COVID-19.

Results: Recent administration of chemotherapy was identified in 20 patients with acute myeloblastic leukaemia and 4 patients with acute lymphoblastic leukaemia. The newly diagnosed patients or those undergoing intensive chemotherapy, in particular elderly patients, had a severe form of COVID-19 and an unfavourable evolution, and these clinical situations were identified as predictive factors for adverse outcomes. Patients with acute lymphoblastic leukaemia had a shorter survival curve compared to patients with acute myeloblastic leukaemia. Pneumonia was present especially in patients with acute myeloblastic leukaemia, most patients having over 30% of lung fields affected (55.26%). Patients with an unfavourable outcome had significantly increased median values of C-reactive protein, procalcitonin and interleukin6.

Conclusions: Patients with acute leukaemia, especially acute myeloblastic leukaemia who have been diagnosed with COVID-19 infection require special attention because they may associate complications and adverse outcomes of COVID-19. The results we obtained require evaluation in a larger group of patients and analysis in the follow-up period after COVID-19.

Keywords

1. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, Di-Nardo C, et al. Treating Leukemia in the Time of COVID-19. Acta Haematol 2021;144:132-45. DOI: 10.1159/00050819910.1159/000508199 Search in Google Scholar

2. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (Accessed on April 5, 2021). Search in Google Scholar

3. Uzzo R, Kutikov A, Geynisman D, Michael B Atkins, Larissa Nekhlyudov, Richard A Larson et al. COVID-19: Risks for infection, clinical presentation, testing, and approach to infected patients with cancer, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on 02 Apr, 2021). Search in Google Scholar

4. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 Jul;10(7):935-41. DOI: 10.1158/2159-8290.CD-20-051610.1158/2159-8290.CD-20-0516 Search in Google Scholar

5. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 May;55:102763. DOI: 10.1016/j.ebiom.2020.10276310.1016/j.ebiom.2020.102763 Search in Google Scholar

6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Apr 6;46(5):846-8. DOI: 10.1007/s00134-020-05991-x10.1007/s00134-020-05991-x Search in Google Scholar

7. Centers for Disease Control and Prevention. Science brief: Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlying-evidence-table.html (Accessed on April 5, 2021). Search in Google Scholar

8. El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date. Br J Haematol. 2020;190: 336-45. DOI: 10.1111/bjh.1695610.1111/bjh.16956 Search in Google Scholar

9. Borah P, Mirgh S, Sharma SK, Bansal S, Dixit A, Dolai TK, et al, AIIMS Hematology Alumni Group. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021 Mar;87:102525. DOI: 10.1016/j.bcmd.2020.10252510.1016/j.bcmd.2020.102525 Search in Google Scholar

10. Popov VM, Iliescu L, Balea MI, Horatiu Ioani, Mihaela Andreescu, Daniela Georgescu, et al. Predictive value of hematologic and coagulation parameters in assessment of severity and evolution of COVID-19 patients. Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X). 2020 October;8(10);605-15. Search in Google Scholar

11. Pi-ana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G. Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 Aug 25;9:21. DOI: 10.1186/s40164-020-00177-z10.1186/s40164-020-00177-z Search in Google Scholar

12. Fattizzo B, Giannotta JA, Sciumè M, Cattaneo D, Bucelli C, Fracchiolla NS, et al. Reply to „COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality. Leukemia. 2020 Jul;34(7):1957-60. DOI: 10.1038/s41375-020-0877-y10.1038/s41375-020-0877-y Search in Google Scholar

13. Liu J, Liu Y, Xiang P, Xiong H, Li C, Zhang M, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. DOI: 10.1186/ s12967-020-02374-010.1186/s12967-020-02374-0 Search in Google Scholar

14. Rubinstein SM, Warner JL. COVID-19 and haemato-logical malignancy: navigating a narrow strait. Lancet Haematol. 2020 Oct;7(10):e701-3. DOI: 10.1016/ S2352-3026(20)30252-010.1016/S2352-3026(20)30252-0 Search in Google Scholar

15. Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, Lin S. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant. 2020 Jul;20(7):1879-81. DOI: 10.1111/ajt.1589610.1111/ajt.15896 Search in Google Scholar

16. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, La-very JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020 Dec 1;130(12):6656-67. DOI: 10.1172/ JCI14177710.1172/JCI141777 Search in Google Scholar

17. Ciccullo A, Borghetti A, Zileri Dal Verme L, Tosoni A, Lombardi F, Garcovich M, et al; GEMELLI AGAINST COVID Group. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020 Aug;56(2):106017. DOI: 10.1016/j.ijantimicag.2020.10601710.1016/j.ijantimicag.2020.106017 Search in Google Scholar

18. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737-45.10.1016/S2352-3026(20)30251-9 Search in Google Scholar

19. Chan AS, Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. J Clin Med Res. 2020 Jul;12(7):448-53. DOI: 10.14740/ jocmr424010.14740/jocmr4240733186132655740 Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo